Salama - support for central drug purchasing

The Global Gateway project supporting Salama, Madagascar's central medicines purchasing and distribution body, remains at the earliest stage of its lifecycle. Classified as Phase 1 of 5 and announced without a publicly disclosed investment figure, there is currently no independently verifiable evidence that financing has been committed or that implementation has begun. The IATI Datastore, which records EU Commission commitments and disbursements, returns no matching financial entries for this project. That absence is a meaningful signal: it suggests that no funds have yet been formally committed under EU accounting frameworks, or that the project has not progressed to a stage at which disbursements would be recorded. Without corroborating data from EIB project records or independent reporting, a business audience should treat this as an intention rather than an active programme. The EU's own description positions Salama as a "key player" in public health supply chains, with particular relevance for women and children. This framing is consistent with Global Gateway's wider messaging priorities, but it should be read as aspirational until confirmed by independent sources. No EU delegation statements or parliamentary records were available to add further institutional detail. Independent news coverage touching on Madagascar's medicines supply landscape is sparse and does not reference this project directly. A March 2026 report from Logistics Update Africa noted a separate USD 10 million US government investment in Madagascar's health supply chain, which underscores that the sector attracts donor interest but also that other actors are moving with more visible momentum.